Background: Invasive fusariosis (IF) affects mostly severely immunocompromised hosts and is associated with poor outcome. Since Fusarium species exhibit high MICs for most antifungal agents, this could explain the poor prognosis. However, a clear-cut correlation between MIC and outcome has not been established. Objective: To evaluate the correlation between MIC and outcome (6 week death rate) in patients with IF. Methods: We performed a multicentre retrospective study of patients with IF who received treatment and had MIC levels determined by EUCAST or CLSI for the drug(s) used during treatment. We compared the MIC50 and MIC distribution among survivors and patients who died within 6 weeks from the diagnosis of IF. Results: Among 88 patients with IF, 74 had haematological diseases. Primary treatment was monotherapy in 52 patients (voriconazole in 27) and combination therapy in 36 patients (liposomal amphotericin B + voriconazole in 23). The MIC50 and range for the five most frequent agents tested were: voriconazole 8 mg/L (range 0.5-64), amphotericin B 2 mg/L (range 0.25-64), posaconazole 16 mg/L (range 0.5-64), itraconazole 32 mg/L (range 4-64), and isavuconazole 32 mg/L (range 8-64). There was no difference in MIC50 and MIC distribution among survivors and patients who died. By contrast, persistent neutropenia and receipt of corticosteroids were strong predictors of 6 week mortality. Conclusions: Our study did not show any correlation between MIC and mortality at 6 weeks in patients with IF.

Do high MICs predict the outcome in invasive fusariosis? / Nucci, M.; Jenks, J.; Thompson, G. R.; Hoenigl, M.; Dos Santos, M. C.; Forghieri, F.; Rico, J. C.; Bonuomo, V.; Lopez-Soria, L.; Lass-Florl, C.; Candoni, A.; Garcia-Vidal, C.; Cattaneo, C.; Buil, J.; Rabagliati, R.; Roiz, M. P.; Gudiol, C.; Fracchiolla, N.; Campos-Herrero, M. I.; Delia, M.; Farina, F.; Fortun, J.; Nadali, G.; Sastre, E.; Colombo, A. L.; Perez Nadales, E.; Alastruey-Izquierdo, A.; Pagano, L.. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 0305-7453. - 76:4(2021), pp. 1063-1069. [10.1093/jac/dkaa516]

Do high MICs predict the outcome in invasive fusariosis?

Candoni A.;
2021

Abstract

Background: Invasive fusariosis (IF) affects mostly severely immunocompromised hosts and is associated with poor outcome. Since Fusarium species exhibit high MICs for most antifungal agents, this could explain the poor prognosis. However, a clear-cut correlation between MIC and outcome has not been established. Objective: To evaluate the correlation between MIC and outcome (6 week death rate) in patients with IF. Methods: We performed a multicentre retrospective study of patients with IF who received treatment and had MIC levels determined by EUCAST or CLSI for the drug(s) used during treatment. We compared the MIC50 and MIC distribution among survivors and patients who died within 6 weeks from the diagnosis of IF. Results: Among 88 patients with IF, 74 had haematological diseases. Primary treatment was monotherapy in 52 patients (voriconazole in 27) and combination therapy in 36 patients (liposomal amphotericin B + voriconazole in 23). The MIC50 and range for the five most frequent agents tested were: voriconazole 8 mg/L (range 0.5-64), amphotericin B 2 mg/L (range 0.25-64), posaconazole 16 mg/L (range 0.5-64), itraconazole 32 mg/L (range 4-64), and isavuconazole 32 mg/L (range 8-64). There was no difference in MIC50 and MIC distribution among survivors and patients who died. By contrast, persistent neutropenia and receipt of corticosteroids were strong predictors of 6 week mortality. Conclusions: Our study did not show any correlation between MIC and mortality at 6 weeks in patients with IF.
2021
76
4
1063
1069
Do high MICs predict the outcome in invasive fusariosis? / Nucci, M.; Jenks, J.; Thompson, G. R.; Hoenigl, M.; Dos Santos, M. C.; Forghieri, F.; Rico, J. C.; Bonuomo, V.; Lopez-Soria, L.; Lass-Florl, C.; Candoni, A.; Garcia-Vidal, C.; Cattaneo, C.; Buil, J.; Rabagliati, R.; Roiz, M. P.; Gudiol, C.; Fracchiolla, N.; Campos-Herrero, M. I.; Delia, M.; Farina, F.; Fortun, J.; Nadali, G.; Sastre, E.; Colombo, A. L.; Perez Nadales, E.; Alastruey-Izquierdo, A.; Pagano, L.. - In: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. - ISSN 0305-7453. - 76:4(2021), pp. 1063-1069. [10.1093/jac/dkaa516]
Nucci, M.; Jenks, J.; Thompson, G. R.; Hoenigl, M.; Dos Santos, M. C.; Forghieri, F.; Rico, J. C.; Bonuomo, V.; Lopez-Soria, L.; Lass-Florl, C.; Candoni, A.; Garcia-Vidal, C.; Cattaneo, C.; Buil, J.; Rabagliati, R.; Roiz, M. P.; Gudiol, C.; Fracchiolla, N.; Campos-Herrero, M. I.; Delia, M.; Farina, F.; Fortun, J.; Nadali, G.; Sastre, E.; Colombo, A. L.; Perez Nadales, E.; Alastruey-Izquierdo, A.; Pagano, L.
File in questo prodotto:
File Dimensione Formato  
dkaa516.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 510.33 kB
Formato Adobe PDF
510.33 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1293938
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 26
social impact